In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

In other Lilly news, the FDA recently approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. The drug is is now approved in the United States ...

Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.

The Global Prefilled Syringes Market was valued at $5.43 billion in 2022 and is projected to reach $10.59 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.70% during the forecast ...

Tablet shows same established efficacy and safety as the Evrysdi oral solution. HealthDay News — The U.S. Food and Drug Administration has approved a new drug application for a tablet version of ...

These include Alzheimer's disease treatment Kisunla, eczema therapy Ebglyss, and ulcerative colitis drug Omvoh. These medicines aren't yet contributing to Eli Lilly's already impressive top-line ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

But Eli Lilly isn’t stopping there. They’re leading an ambitious charge with their new star, Omvoh, proving effective for patients with stubborn cases of Crohn’s disease. This drug achieved notable ...